Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Gap Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $285.55 (market cap $39.89B), while Gap Inc trades at $19.67 (market cap $7.01B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.7× Gap Inc's market cap, and Gap Inc pays a 3.6% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GAP | |
|---|---|---|
Market Cap | $39.89B | $7.01B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $29.13 |
52-Week Low | $278.09 | $18.35 |
Enterprise Value | $38.15B | $10.09B |
Dividend Yield | — | 3.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Gap Inc. (GAP) trades at $19.46, up 3.24% today, with a bearish technical outlook but attractive valuation metrics including a P/E of 7.72 and P/S of 0.48. Recent earnings show mixed results with a Q1 2026 beat but a Q4 2025 miss. The company demonstrates strong profitability with a net income margin of 6.25% and ROE of 27.58%, supported by positive operating cash flow of $1.49 billion in 2025. News highlights include ongoing investigations by law firms and digital transformation efforts.
The stock presents a value opportunity with a consensus price target of $27.00, implying significant upside, but faces risks from legal scrutiny and competitive pressures. Analyst sentiment is mixed with 39.58% buy ratings, while technical indicators suggest near-term weakness. Revenue growth remains modest, projected at $15.4 billion for 2026, with earnings stability key to unlocking value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
